The Evolution of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukemia

Dristhi Ragoonanan; Irtiza N. Sheikh; Sumit Gupta; Sajad J. Khazal; Priti Tewari; Demetrios Petropoulos; Shulin Li; Kris M. Mahadeo

doi:10.3390/biomedicines10092286

The Evolution of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukemia

Dristhi Ragoonanan, Irtiza N. Sheikh, Sumit Gupta, Sajad J. Khazal, Priti Tewari, Demetrios Petropoulos, Shulin Li, Kris M. Mahadeo

Pediatrics

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Chimeric antigen receptor T-cell (CAR T) therapy is a revolutionary treatment for pediatric, adolescent and young adult patients (AYA) with relapsed/refractory B-cell acute lymphoblastic leukemia. While the landscape of immunotherapy continues to rapidly evolve, widespread use of CAR T therapy is limited and many questions remain regarding the durability of CAR T therapy, methods to avoid CAR T therapy resistance and the role of consolidative stem cell transplant. Modified strategies to develop effective and persistent CAR T cells at lower costs and decreased toxicities are warranted. In this review we present current indications, limitations and future directions of CAR T therapy for ALL in the pediatric and AYA population.

Original language	English (US)
Article number	2286
Journal	Biomedicines
Volume	10
Issue number	9
DOIs	https://doi.org/10.3390/biomedicines10092286
State	Published - Sep 2022

Keywords

acute lymphoblastic leukemia
ALL
Bispecific CART
CART
CD19
CD22
chimeric antigen receptor

ASJC Scopus subject areas

Medicine (miscellaneous)
General Biochemistry, Genetics and Molecular Biology

Access to Document

10.3390/biomedicines10092286

Cite this

@article{fd277f3343574ea6a59768014218d952,

title = "The Evolution of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukemia",

abstract = "Chimeric antigen receptor T-cell (CAR T) therapy is a revolutionary treatment for pediatric, adolescent and young adult patients (AYA) with relapsed/refractory B-cell acute lymphoblastic leukemia. While the landscape of immunotherapy continues to rapidly evolve, widespread use of CAR T therapy is limited and many questions remain regarding the durability of CAR T therapy, methods to avoid CAR T therapy resistance and the role of consolidative stem cell transplant. Modified strategies to develop effective and persistent CAR T cells at lower costs and decreased toxicities are warranted. In this review we present current indications, limitations and future directions of CAR T therapy for ALL in the pediatric and AYA population.",

keywords = "acute lymphoblastic leukemia, ALL, Bispecific CART, CART, CD19, CD22, chimeric antigen receptor",

author = "Dristhi Ragoonanan and Sheikh, {Irtiza N.} and Sumit Gupta and Khazal, {Sajad J.} and Priti Tewari and Demetrios Petropoulos and Shulin Li and Mahadeo, {Kris M.}",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors.",

year = "2022",

month = sep,

doi = "10.3390/biomedicines10092286",

language = "English (US)",

volume = "10",

journal = "Biomedicines",

issn = "2227-9059",

publisher = "MDPI AG",

number = "9",

}

TY - JOUR

T1 - The Evolution of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukemia

AU - Ragoonanan, Dristhi

AU - Sheikh, Irtiza N.

AU - Gupta, Sumit

AU - Khazal, Sajad J.

AU - Tewari, Priti

AU - Petropoulos, Demetrios

AU - Li, Shulin

AU - Mahadeo, Kris M.

PY - 2022/9

Y1 - 2022/9

N2 - Chimeric antigen receptor T-cell (CAR T) therapy is a revolutionary treatment for pediatric, adolescent and young adult patients (AYA) with relapsed/refractory B-cell acute lymphoblastic leukemia. While the landscape of immunotherapy continues to rapidly evolve, widespread use of CAR T therapy is limited and many questions remain regarding the durability of CAR T therapy, methods to avoid CAR T therapy resistance and the role of consolidative stem cell transplant. Modified strategies to develop effective and persistent CAR T cells at lower costs and decreased toxicities are warranted. In this review we present current indications, limitations and future directions of CAR T therapy for ALL in the pediatric and AYA population.

AB - Chimeric antigen receptor T-cell (CAR T) therapy is a revolutionary treatment for pediatric, adolescent and young adult patients (AYA) with relapsed/refractory B-cell acute lymphoblastic leukemia. While the landscape of immunotherapy continues to rapidly evolve, widespread use of CAR T therapy is limited and many questions remain regarding the durability of CAR T therapy, methods to avoid CAR T therapy resistance and the role of consolidative stem cell transplant. Modified strategies to develop effective and persistent CAR T cells at lower costs and decreased toxicities are warranted. In this review we present current indications, limitations and future directions of CAR T therapy for ALL in the pediatric and AYA population.

KW - acute lymphoblastic leukemia

KW - ALL

KW - Bispecific CART

KW - CART

KW - CD19

KW - CD22

KW - chimeric antigen receptor

UR - http://www.scopus.com/inward/record.url?scp=85138651880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85138651880&partnerID=8YFLogxK

U2 - 10.3390/biomedicines10092286

DO - 10.3390/biomedicines10092286

M3 - Review article

C2 - 36140387

AN - SCOPUS:85138651880

SN - 2227-9059

VL - 10

JO - Biomedicines

JF - Biomedicines

IS - 9

M1 - 2286

ER -

The Evolution of Chimeric Antigen Receptor T-Cell Therapy in Children, Adolescents and Young Adults with Acute Lymphoblastic Leukemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this